Uganda Implements Nationwide Newborn Screening for Sickle Cell Disease Amidst Challenges of Gene Therapy Accessibility
Kampala, Uganda – This month marks a significant step forward in public health as Uganda launches mandatory newborn screening for sickle cell disease (SCD) across all health facilities. The initiative aims to identify affected infants at birth, facilitating early treatment to combat one of the leading causes of death among young children in the region. However, it coincides with a stark reminder of the limitations around advanced medical treatments like gene therapy, which remain financially out of reach for most patients in Africa.
According to the World Health Organization, approximately 515,000 babies are born annually with sickle cell disease, predominantly in Sub-Saharan Africa, where the condition is particularly deadly. In Uganda alone, government estimates indicate that around 20,000 children are born with SCD each year. Alarmingly, 80% of these cases result in death before the age of five due to delays in diagnosis and related complications.
Ayoola Olajide, president of the Ikorodu Sickle Cell Club in Nigeria, reflected on the situation, stating, “For Africa, gene therapy treatment currently exists only on paper.” He emphasized the significant gap between hope and reality, especially given the exorbitant costs associated with emerging therapies celebrated in developed nations.
While some countries have started to embrace gene therapy—seen as a potential cure for SCD—many families in Africa continue to struggle with basic healthcare. Elisha Osati, chairman of the Tanzania Sickle Cell Disease Alliance, shared a similar sentiment, asserting, “Yes, gene therapy brings hope but it’s a hope that’s almost impossible for our people because of the cost.” He called for increased collaboration and investment in local medical capabilities to alleviate this situation.
Potential of Gene Therapy
Recent advancements have led to the approval of gene editing therapies such as Casgevy (exagamglogene autotemcel) in the U.S. and UK. These groundbreaking treatments aim to alter patients’ blood stem cells to produce healthy red blood cells, reducing severe pain episodes experienced by individuals with SCD. Unfortunately, the financial barrier remains steep; Casgevy is priced at an astonishing $2.2 million in the United States, leaving those in low- and middle-income countries with little hope of accessing the therapy even if it becomes available.
In Nigeria, where the burden of sickle cell disease is the highest globally, with roughly 150,000 new cases each year, Olajide noted that such treatments remain symbolic. “You must be extremely wealthy to even think about it,” he explained. The high costs of treatments have led many to seek options abroad, creating further inequalities in a healthcare system that already struggles to provide basic care.
Challenges in Treatment Accessibility
For decades, treatment in Africa has largely focused on managing symptoms rather than eradicating the disease. Pain relief, blood transfusions, and, in limited cases, bone marrow transplants have been the mainstays of care. However, these transplants can cost between $50,000 and $200,000, making them unaffordable for many.
Osati also highlighted the advantage of gene therapy over bone marrow transplantation, as it eliminates the need for a donor, a common issue in Africa due to lower match rates. He stressed the immediate need for making treatments accessible to the population.
Lois Bayigga, a research scientist at Uganda’s Joint Clinical Research Centre, underscored that the high costs associated with gene therapy are reflective of complex manufacturing processes. “If viral vectors and gene therapy components were manufactured locally, pricing would drop significantly,” she stated. Researchers like Bayigga are working towards simplifying production processes to make gene therapies more feasible in local settings.
The Need for Local Solutions
As gene therapy garners attention in wealthier nations, advocates emphasize the importance of immediate action by African governments to focus on prevention, screening, and accessible treatments. Bayigga pointed out that Africa carries the world’s highest burden of inherited blood disorders and called for significant investment in local solutions.
In line with this, Uganda’s new policy for newborn screening is being hailed as a crucial step toward early detection. It ensures that babies born in healthcare facilities receive the necessary diagnostics without incurring any costs. Yet, experts warn that without addressing broader access issues, advancements in curative therapies could lead to greater inequalities within the healthcare system.
“There’s a risk of creating a situation where only some benefit from cures,” Bayigga cautioned. “If a cure exists but is inaccessible, it creates hope for some, but pain for others who know they will never have access to it.”
With ongoing discussions about advancements in medical technology, the onus is on governments, healthcare providers, and communities in Africa to prioritize long-term strategies that ensure equitable healthcare for all citizens.
— Reported by Nexio News
